Trials / Completed
CompletedNCT00088608
A Study to Assess SOM230 in Patients With Pituitary Cushing's Disease
A Multicenter, Open Label Study to Assess the Safety and Efficacy of 600 µg SOM230, Administered Subcutaneously, b.i.d. in Patients With Cushing's Disease
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The study treatment period is 15 days in length and includes patients with pituitary Cushing's disease who are candidates for surgical intervention as well as and patients who have recurrent Cushing's post operatively.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SOM230 s.c. |
Timeline
- Start date
- 2004-04-01
- Primary completion
- 2006-06-01
- First posted
- 2004-08-02
- Last updated
- 2016-11-07
Locations
5 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00088608. Inclusion in this directory is not an endorsement.